Q2-osavuosiraportti
Vain PDF
7 päivää sitten
Tarjoustasot
Määrä
Osto
105
Myynti
Määrä
900
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,72VWAP
Alin
3,32VaihtoMäärä
1,5 660 333
VWAP
Ylin
3,72Alin
3,32VaihtoMäärä
1,5 660 333
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2025 Yhtiökokous | 20.6. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.3. |
Datan lähde: Morningstar, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
4.8.4.8.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
30.1.30.1.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”- 29.1.29.1.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q2-osavuosiraportti
Vain PDF
7 päivää sitten
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 4.8.4.8.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
- 30.1.30.1.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”
- 29.1.29.1.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
105
Myynti
Määrä
900
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,72VWAP
Alin
3,32VaihtoMäärä
1,5 660 333
VWAP
Ylin
3,72Alin
3,32VaihtoMäärä
1,5 660 333
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2025 Yhtiökokous | 20.6. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.3. |
Datan lähde: Morningstar, Quartr
Q2-osavuosiraportti
Vain PDF
7 päivää sitten
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q2-osavuosiraportti | 14.8. | |
| 2025 Yhtiökokous | 20.6. | |
| 2025 Q1-osavuosiraportti | 9.5. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Q4-osavuosiraportti | 21.3. |
Datan lähde: Morningstar, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 4.8.4.8.🚀🚀🚀🚀🚀🚀🚀🚀 NEW YORK, Aug. 4, 2025 /CNW/ -- As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's "Make America Healthy Again" initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) (Profile) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. The company is one of several impressive companies committed to making an impact in the pharmaceutical space,
- 30.1.30.1.January 14 Soligenix announced an interim update on the open-label, investigator-initiated study evaluating extended HyBryte – synthetic hypericin – treatment for up to 12 months in patients with early-stage cutaneous T-cell lymphoma, or CTCL. To date, nine patients have been enrolled and treated with HyBryte over a time period of up to 54 weeks. Patients have responded positively to HyBryte therapy, with over 70% already achieving “Treatment Success”, predefined as a greater than or equal to 50% improvement in the cumulative mCAILS score compared to Baseline. Of the five Treatment Successes, three were achieved within the first 12 weeks of treatment, with two patients achieving a “complete response” by 18 weeks. In addition, HyBryte appears to be safe and well tolerated in all patients. Dr. Kim, Lead Investigator of the FLASH2 study, stated, “In the first Phase 3 FLASH study, HyBryte was shown to be efficacious with a benign safety profile compared to the current therapies of steroids, chemotherapeutics and ultraviolet light in this chronic orphan disease…In our FDA-funded study, initial results evaluating the expanded use of HyBryte in a “real world” treatment setting remain very promising, further supporting and extending results from the previous positive Phase 2 and 3 clinical trials. We look forward to continuing to work with the FDA to complete this study while we participate in the confirmatory Phase 3 placebo-controlled FLASH2 study.”
- 29.1.29.1.These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Phio Pharmaceuticals (PHIO), 39,675% surge in interest Eterna Therapeutics (ERNA), 11,117% surge in interest Salarius Pharmaceuticals (SLRX), 10,853% surge in interest Kairos Pharma (KAPA), 2,805% surge in interest Soligenix (SNGX), 1,913% surge in interest Silexion Therapeutics (SLXN), 1,717% surge in interest Azitra (AZTR), 1,645% surge in interest Black Diamond Therapeutics (BDTX), 1,315% surge in interest iBio (IBIO), 935% surge in interest GT Biopharma (GTBP), 900% surge in interest
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
105
Myynti
Määrä
900
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,72VWAP
Alin
3,32VaihtoMäärä
1,5 660 333
VWAP
Ylin
3,72Alin
3,32VaihtoMäärä
1,5 660 333
Välittäjätilasto
Dataa ei löytynyt